title: EORTC New Drug Development Office coordinating and monitoring programme for phase I and II trials with new anticancer agents.
authors.affiliation: EORTC-NDDO, Free University Hospital, Amsterdam, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Schwartsmann
authors.forename: J
authors.initials: J
authors.lastname: Wanders
authors.forename: I J
authors.initials: IJ
authors.lastname: Koier
authors.forename: H R
authors.initials: HR
authors.lastname: Franklin
authors.forename: O
authors.initials: O
authors.lastname: Dalesio
authors.forename: H W
authors.initials: HW
authors.lastname: Hornstra
authors.forename: M
authors.initials: M
authors.lastname: van Glabbeke
authors.forename: J
authors.initials: J
authors.lastname: Renard
authors.forename: A T
authors.initials: AT
authors.lastname: Van Oosterom
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002985:Clinical Protocols; D002986:Clinical Trials as Topic; D015195:Drug Design; D004341:Drug Evaluation; D004992:Ethics, Medical; D005062:European Union; D006801:Humans; D007880:Legislation, Drug; D011358:Product Surveillance, Postmarketing
chemical_list: D000970:Antineoplastic Agents